Affymetrix Posts 12 Percent Revenue Drop, Amends Deal for eBioscience | GenomeWeb

NEW YORK (GenomeWeb News) – Affymetrix reported after the close of the market on Thursday that revenues in the first quarter dropped 12 percent year over year.

The Santa Clara, Calif.-based microarray company also announced separately that it has signed an amended deal to acquire eBioscience for $315 million in cash.

Affy's revenues for the three months ended March 31 dropped to $65.2 million, down from $73.7 million a year ago, but still above Wall Street estimates of $64.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.